Amphipathic peptide

Inventors

McCarthy, Helen • Zholobenko, Aleksey • Davison, Ashley • Robson, Tracy

Assignees

Seqirus Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10500287-B2

Patent

Publication Date

2019-12-10

Expiration Date


Abstract

The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy. For example, the peptide may be used as a therapeutic agent delivery system, in which the therapeutic agent may include nucleic acids or other small molecules.

Core Innovation

The independent claim describes a nanoparticle comprising an amphipathic cell-penetrating peptide of fewer than 50 amino acid residues complexed with a nucleic acid or other agent. The peptide comprises defined counts of arginine, alanine, leucine, cysteine, and glutamic acid residues, with arginine residues evenly distributed along its length. It features specified arginine-to-glutamic-acid and hydrophilic-to-hydrophobic amino acid residue ratios.

The nanoparticles provide cellular and nuclear delivery of payloads, encompassing DNA, RNA or siRNA, bisphosphonate drugs, and gold. The disclosure demonstrates nanoparticle encapsulation, complexation stability, serum protection, cellular uptake, transfection efficiency, and in vivo delivery across peptide variants and cell models. Reported outcomes include reduced Runx2 expression, delayed tumor growth, enhanced cellular activity of bisphosphonates such as alendronate, and improved gold cellular uptake.

Claims Coverage

The provided relevant claims identify one independent claim covering a nanoparticle with five inventive features.

Amphipathic cell-penetrating peptide composition

The nanoparticle comprises an amphipathic cell-penetrating peptide of less than 50 amino acid residues, comprising at least 6 arginine residues, at least 12 alanine residues, at least 6 leucine residues, at least one cysteine residue, and at least two but no greater than three glutamic acid residues.

Even distribution of arginine residues

The arginine residues are evenly distributed along the length of the peptide.

Arginine-to-glutamic-acid ratio

The ratio of arginine residues to negatively charged glutamic acid residues is from at least 6:2 to 8:2.

Hydrophilic-to-hydrophobic residue ratio

At pH 7, the ratio of hydrophilic amino acid residues to hydrophobic amino acid residues is at least 30:70 to 40:60.

Complexation with a payload

The peptide is complexed with a nucleic acid or other agent.

The independent claim centers on a nanoparticle that combines a nucleic acid or other agent with an amphipathic cell-penetrating peptide having specified residue content, distribution, and ratios.

Stated Advantages

The summarized results report reduced Runx2 expression following delivery of Runx2 siRNA by RALA formulations.

The summarized results report delayed tumor growth with RALA formulations delivering Runx2 siRNA and with RALA/alendronate.

RALA-complexed bisphosphonates show enhanced cellular activity, including a reduced alendronate EC50 compared with free alendronate.

The disclosure reports serum stability of the nanoparticles and serum protection of associated nucleic acids.

The disclosure reports cellular transfection and in vivo delivery across peptide variants and cell models.

The disclosure identifies improving phosphate-based drug bioavailability and improving gold cellular uptake as outcomes of administration.

Documented Applications

Administration of the nanoparticle to treat an individual.

Delivery of nucleic-acid payloads, including DNA, RNA, siRNA (such as Runx2 siRNA), and iNOS-encoding constructs, for gene therapy and cellular or nuclear delivery.

Delivery of phosphate-based drugs, including nitrogen- or non-nitrogen-based bisphosphonate drugs such as alendronate, etidronate, or zolendrate, directed to improving drug bioavailability.

Delivery of gold directed to improving gold cellular uptake.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.